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Ecological validity of cost-effectiveness 
models of universal HPV vaccination: a 
systematic literature review. 
1. Introduction 
The discovery of a causal relationship of human papillomavirus (HPV) to cancers is 
relatively recent, with the 2008 Nobel Prize in Medicine awarded to Harald zur 
Hausen [1]. Vaccines against HPV have now been licensed for a decade: a 
quadrivalent HPV vaccine (four strains of HPV: 6, 11, 16, 18) Gardasil®, has been 
licensed for prevention of cervical cancer within the USA and Europe since 2006 by 
the US Food and Drug Administration, and European Medicines Agency, 
respectively [2,3], and a bivalent vaccine (two strains: 16, 18) Cervarix®, has been 
licensed in Europe since 2007 and the USA since 2009 [4,5]. A more recent 
development, the nonavalent HPV vaccine (nine strains: 6, 11, 16, 18, 31, 33, 45, 
52, 58) has been licensed in the USA since 2014 and Europe since 2015 [6,7]. 
With the availability of new prophylactic HPV vaccines, policy makers have been 
asked to make choices regarding the most cost-effective immunisation strategies to 
reduce HPV infection and associated burden of disease [8]. The question of whether 
males should be vaccinated stems from the recognition that male HPV infection 
significantly contributes to the burden of HPV-induced diseases [9]. 
Epidemiological and economic models have been used to inform this decision 
making. Increasing demand for modelling resulted in the development and 
publication of numerous complex statistical models looking at the efficacy and cost-
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effectiveness of the available HPV vaccines and screening programmes deployed in 
immunisation strategies [10].  
The prevailing policy option resulting from this sophisticated approach has been the 
selective vaccination of pubertal girls [11]. The protective effect of selective 
immunisation can be described as the probability (function of the vaccination 
coverage) that one of the two partners involved in intercourse is successfully 
immunised, hence preventing the other from infection [12]. This “herd immunity” 
effect depends on vaccination coverage and vaccine efficacy [10]. Assuming lifelong 
protection from vaccination, the annual selective immunisation of 80% of 12-year-old 
school girls would result in the elimination of HPV vaccine types [13]. For herd 
immunity to be assured, a truly representative “risk of exposure” (i.e. all the ways in 
which the infection can be transmitted) should be established and use in scenario 
modelling. Case controlled studies have demonstrated that men’s sexual behaviour 
affects women’s risk for HPV-induced malignancies, even when controlling for 
female sexual activity [14-17]. Although previously published systematic reviews 
[10,18,19] showed that most cost-effectiveness studies in the extant literature have 
demonstrated the cost-effectiveness of selective high coverage (>80%) of 12-year-
old girls, an increasing number of medical associations advocate the need for 
universal vaccination against HPV. The American Society of Clinical Oncology 
(ASCO) recognises the long latent period of HPV infection prior to the development 
of invasive cancers means many years of follow-up are required to demonstrate a 
significant reduction in HPV-related cancers; it recommends, along with the US 
Centre for Disease Control (CDC) that all boys and girls are vaccinated at 11 or 12 
years old, prior to possible HPV exposure through consensual sexual activity [20].  
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Despite this clinical advice, public health policy makers in most European Countries 
(except Austria, Sweden and some regions of Italy) have, to date, largely accepted 
the published cost-effectiveness modelling based on the protective effect of herd 
immunity, and have implemented girls-only vaccination programmes [21]. 
The epidemiological and economic models used to inform public health decisions 
should include all known dynamics of transmission of infection along with the 
populations affected. HPV is primarily transmitted via penetrative sexual intercourse, 
although there is evidence of other modes of transmission, including transmission 
from hands to genitals or genitals to hands [22]. Hence cost-effectiveness valuations 
of HPV vaccination strategies should include consideration of sexual behaviours and 
population mixing. Behaviours must be provided for in any economic modelling for 
the outcome to demonstrate ecological validity, whereby the scenarios modelled 
remain faithful to the real-life social and cultural context [23].  
Ecological validity is of clear importance when informing a public healthcare 
decision, and modelling should therefore have a generalised relationship to the 
natural behaviours of the affected population; in the case of HPV vaccination, this 
should be based on the inclusion of the representative individuals within the 
population and the sexual behaviours they undertake. The primary aim of this review 
is therefore to test the ecological validity of the universal HPV vaccination cost-
effectiveness modelling available in the published literature; each model will be 
defined by the number of representative characteristics and behaviours taken into 
consideration. 
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2. Methods 
The research protocol related to this systematic review has been registered in the 
International Prospective Register of Systematic Reviews (PROSPERO: 
CRD42016034145), available online at: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016034145. 
A full description of the research methodology has been published [24].  
Inclusion criteria for the literature included in the review were for (a) studies reporting 
the incremental cost effectiveness ratio (ICER) per quality-adjusted year gained 
(QALY) of adding males to a female-only HPV vaccination; (b) health outcomes not 
limited to cervical cancer and genital warts, but including additional HPV-induced 
diseases such as vulval cancer, vaginal cancer, anal cancer, penile cancer, oro-
pharyngeal cancer, recurrent respiratory papillomatosis (RRP); (c) HPV universal 
vaccination compared to cervical cancer screening and vaccination of females only; 
(d) studies reporting a full disclosure of the inputs chosen to inform the economic 
model; (e) economic models that were individual, static, transmission dynamic or 
hybrid models. 
Health outcomes limited to the valuation of cervical cancer and genital warts, and 
studies not published in the English language, were excluded.  
2.1 Search Strategy 
The literature search is outlined in the PRISMA flow diagram [25] reported in Figure 
1.  
 
Figure 1 should go approximately here. 
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Two Graduate Research Associates (GRAs) independently identified relevant 
literature through database searching, and then screened and assessed for eligibility 
to include in the review. Opinion of one of the reviewers (authors) was sought to 
arrive at a consensus in the case of disagreement. Nine bibliographic databases 
were searched for literature: MEDLINE (via PubMed); Scopus; Science Direct; 
EMBASE via OVID SP, Web of Science, DARE, NHS EED and HTA (via CRD); 
CINHAL Plus. An additional search for grey literature was conducted on 
GoogleScholar and OpenGrey, and search results were screened and assessed for 
eligibility of inclusion according to the PRISMA 2009 process [25]. To reduce the risk 
of missing original articles, reviews were included, the PubMed “related articles” 
search feature was used, and references of the included studies were also searched 
in order to identify any additional missed relevant studies. The search terms used in 
the search strategy are included as Appendix A. A pilot of the study selection 
process was conducted before initiating the systematic search of relevant articles.  
Two external experts (a health economist and a clinical oncologist) independently 
assessed the risk of bias for each of the studies included in the review. The critical 
appraisal of the included economic evaluations was carried out in two subsequent 
stages: 
- A preliminary stage, aimed to assess the risk of bias in the estimates of 
treatment effect (e.g. vaccine efficacy) used as data inputs in the economic 
evaluation.  Although the efficacy of HPV immunisation has been preliminarily 
confirmed by small-sample cohort studies (n=29), the choice of the Cochrane 
Risk of Bias tool [26] was based on the premise that the body of primary studies 
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informing the estimates of relative treatment effect in cost-effectiveness models 
is still represented by the randomised clinical trials that supported the regulatory 
approval of the HPV vaccines currently available [27]. The Cochrane Risk of 
Bias tool is reported in Appendix B. 
- A main stage, aimed to identify additional risks of bias and, ultimately, to assess 
the validity of the included studies. The risk assessment will follow the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
approach [28]. The CHEERS statement is reported in Appendix C.  
The main findings were summarised according to the PRISMA checklist for 
assessing susceptibility to bias in health economic valuation [25], reported in 
Appendix D.  
2.2 Data extraction 
Data were extracted and recorded independently by two additional Graduate 
Research Associates (GRAs) from the studies included in the review, according to a 
predefined data extraction table. Data extracted were clustered and prioritised: the 
main outcomes report the inputs to the demographic and epidemiological model, 
while additional outcomes refer to basic inputs to the cost-effectiveness valuation. 
The ecological validity of each model was defined by the representative population 
and behaviours taken into consideration within the modelling.  
Population characteristics and behaviours were defined according to the extant 
literature [29,30]. In relation to the population modelled: (a) the number of 
susceptible individuals (population size and growth); (b) gender; (c) age; (d) 
ethnicity; (e) self-defined sexual identity. In relation to sexual behaviours: (a) sexual 
activity, defined as the rate of change of sexual partners; (b) concurrent sexual 
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partnerships; (c) at least one sexual partner from outside the UK; (d) paid-for sex; (e) 
the frequency of unprotected (without condom) sex. Sexual behaviours data refer to 
men only, since women are actively protected by the selective vaccination against 
HPV in all the cost-effectiveness models included in the systematic review (see 
inclusion criteria a).  
Monetary values were converted into US dollars (where required) using purchasing 
power parities (PPPs), and further adjusted to 2015 US dollar value using the US 
Consumer Price Index (CPI).  
2.3 Data synthesis 
Each study included in the review was scored by the number of representative 
population characteristics and behaviours considered. The individual study’s scores 
were plotted on a 2x2 matrix plotting sexual behaviours on the x axis, and 
characteristics of participants on the y axis, a modified structure from Hogarth (2005) 
[31]. Studies included in the upper right quadrant can therefore be defined as 
ecologically valid through high levels of consideration of population characteristics 
and behaviours; it is these studies that provide more representative scenarios to 
inform economic recommendations on public health policies.  
3. Results 
3.1 Search results 
The database search identified 525 publications, and an additional 46 were 
discovered through open sources; this consisted of 173 studies after duplicate 
records were removed (Figure 1). Following exclusion of models that did not account 
for incremental cost-effectiveness ratio (ICER) associated with male HPV 
vaccination, 21 individual records remained (16 full text articles and five reviews). Of 
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these, all the reviews were excluded (following confirmation they did not include any 
new original articles), and eight published articles were excluded because outcomes 
did not include all HPV-induced disease. This resulted in eight original studies to be 
included in the review for data extraction: Elbasha and Dasbach, 2010 [32]; Kim and 
Goldie, 2009 [33]; Chesson et al., 2011 [34]; Burger et al., 2014 [35]; Laprise et al., 
2014 [36]; Pearson et al., 2014 [37]; Olsen and Jørgensen, 2015 [38]; and Haeussler 
et al., 2015 [39]. 
The independent assessment for risk of bias identified two main findings. Firstly, 
three studies to be included in the review (Elbasha and Dasbach, 2010; Pearson et 
al., 2014; Olsen and Jørgensen, 2015) used unreferenced estimates of vaccine 
efficacy to inform the cost-effectiveness model [27,32,38]. The efficacy estimates 
used to inform these models were in the same range (90 to 100% vaccine efficacy) 
as the outcomes of randomised clinical trials used by all other studies included in the 
review. 
Secondly, the three studies which recommended the cost-effectiveness of universal 
vaccination (Elbasha and Dasbach, 2010; Olsen and Jørgensen, 2015; and 
Haeussler et al., 2015) were funded by a research grant from Sanofi Pasteur MSD, a 
leading supplier of HPV vaccine [32,38,39]. Source of funding and conflict of interest 
were appropriately reported by the Authors.  
These findings would represent a marginal risk of bias for the outcomes of this 
review, since they are virtually irrelevant to the assessment of the ecological validity 
of each model, which is the main objective of research. The independent reviewers 
and the Authors agreed to include in the review the eight studies identified through 
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the database search. The relative impact of input choices on cost-effectiveness 
outcomes will be further discussed in the following sections. 
3.2 Summary of cost-effectiveness outcomes 
Cost-effectiveness studies represents the normative side of health economics, using 
models to facilitate decision making from the perspective of making the most efficient 
use of limited resources [40]. The policy recommendations emerging from the extant 
literature on universal vaccination against HPV have been contradictory, although all 
the included studies analysed averted direct medical costs only, from a societal or 
health payer perspective. The universal vaccination against HPV resulted as cost-
effective in three studies [32,38,39]; possibly cost-effective in two studies, secondary 
to increasing immunisation coverage of women [34,35]; and ultimately never cost-
effective according to three studies [33,36,37]. 
The inputs chosen to inform the cost-effectiveness models included in this 
systematic review are reported in Table 1. 
Table 1 should go approximately here 
3.3 Summary of inputs to demographic and epidemiological method.  
The inputs to the infection diffusion models (participant characteristics and sexual 
behaviours) utilised by the cost-effectiveness studies included in the review are 
reported in Table 2. 
Table 2 should go approximately here 
The results of the review for ecological validity demonstrated differences in the 
modelling of the population and behaviour. None of the studies considered the 
impact of sexual partners from outside the population (either within the country or 
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overseas), sex that was paid for, or the frequency of unprotected sex. Only one of 
the models [36] considered men who have sex with men (MSM) as a self-defined 
sexual identity, but none of the models considered single or occasional same-sex 
partnerships, where sexual identity may not be self-defined as MSM or bisexual.     
The results were plotted on a 2x2 matrix (sexual behaviours on the x axis, and 
characteristics of participants on the y axis). Figure 2 demonstrates the outcome. 
Figure 2 should go approximately here. 
None of the studies showed due consideration of the complexities of human sexual 
behaviour and the impact this may have on the economic modelling; this can be 
seen by the lack of entries on the right of Figure 2. A study of the cost-effectiveness 
of HPV universal vaccination with ecological validity would be present in quadrant A 
of Figure 2. On this basis, all the included models might be affected by a different 
degree of ecological bias, which implies an inability to reflect the natural 
demographic and behavioural trends in their outcomes and, consequently, to 
accurately inform public healthcare policy. 
4. Discussion 
Our results are consistent with the outcomes of recently published reviews of HPV 
vaccination modelling approaches [41,42,43]. The heterogeneity of outcomes 
observed in the reviewed studies results from the high degree of sensitivity to 
boundary conditions and the choice of inputs [39]. The incremental cost 
effectiveness ratio (ICER) values increase as a consequence of higher vaccine 
efficacy, duration of protection, cross-protection, duration of immunisation, and 
observation period. Conversely, ICER values decrease as a consequence of 
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including a larger set of HPV-induced diseases (such as recurrent respiratory 
papillomatosis), lifetime duration of efficacious vaccination (no subsequent “booster” 
dose), a reduced number of doses needed to complete immunisation (two versus 
three) and a lower unit price per vial of the vaccine. Funding might also play a role in 
the choice of the inputs to inform the economic models. 
Therefore, the difference between the observed ICER values and the acceptability 
threshold (usually $50,000 or £30,000) may result as positive (adding boys is not 
cost-effective) or negative (universal vaccination is cost-effective), simply on the 
basis of the prevalent effect of the mix of inputs chosen to inform the model on the 
ICER value. As an illustrative example, the highest ICER (in $2015 values) observed 
among the studies included in the systematic review was >$200,000 [34]. The 
reported ICER value was driven by the highest level of immunisation coverage 
observed in the review (75% of all 12-26 year-old women, a 13-26 year-old women 
catch-up cohort and 75% of all 12 year-old males), by an elevated (90 to 100%) 
adherence to a three-dose vaccination schedule, and by a relatively high vaccine 
price ($128 per vial). 
In more general terms, sensitivity analyses showed that the vaccine price per vial is 
one of the factors most relevant to the determination of the incremental cost-
effectiveness ratio, and hence of the cost-effectiveness of universal vaccination 
(Table 1). All else equal, a vaccine price per vial of $31.47/£22.03/€28.01 would 
drive all the base-case ICER values reported by the studies included in the review 
below an acceptability threshold of $50,000 (in $2015 values, using the average 
2015 dollar: pound and dollar: euro exchange rates, Bloomberg data). A vaccine 
price per vial of $26.97/ £18.88/€24.00 would drive all the base case ICER values 
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below an acceptability threshold of £30,000. Calculations are reported in Appendix 
E. 
The importance of the price per vial values, probably deemed insignificant inputs at 
the time of the cost-effective analyses, seem quite realistic almost a decade after the 
first introduction of the HPV vaccines in 2007.  In Italy, the price of Cervarix® (GSK) 
dropped to €28.60 per vial by late 2015 [44], while the lowest price observed for 
Gardasil® (Sanofi Pasteur MSD) was €33.90 per vial [45]. 
The volatility implied in the ICER values, a consequence of the large variance 
observed in the chosen economic inputs over time, suggests the need for an 
“expiration date” on the validity of the normative outcomes stemming from cost-
effectiveness analyses. Economic and demographic inputs, however, are not the 
only parameters exposed to significant change over time. In the case of HPV 
vaccination, inputs related to the efficacy of the new vaccines to prevent HPV-
induced malignancies have been on the basis of the results of a few large 
randomised clinical trials submitted for regulatory approval [46-55]. The observed 
inputs ranged from a minimum of 50% clinical efficacy (specifically to head and neck 
cancer [39]) to a maximum of 100% [33,35,38].  
Over the last decade, the impact of HPV vaccination in real-world settings has 
become increasingly evident: maximal reductions of ~90% for HPV 6/11/16/18 
infection, ~90% for genital warts, ~60% for low-grade cytological cervical 
abnormalities, and ~90% for high-grade histologically-proven cervical abnormalities 
have been reported [56]. On the basis of the inputs related to vaccine efficacy, it is 
probable that six out of the eight studies included in this review have over-estimated 
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the benefits gained from the selective vaccination of pubertal girls only, consequently 
making the option to add boys to the HPV immunisation cost-ineffective [33-38].  
The primary aim of this review of the cost-effectiveness models of universal HPV 
vaccination available in the literature was to test their ecological validity, the implicit 
condition that the characteristics and sexual behaviours of the individuals observed 
in the models are representative of, and relational to, the natural behaviours of the 
population. The ecological validity of each model was defined by the number of 
representative characteristics and behaviours of the population taken into 
consideration [29]. Table 2 reports the representative characteristics and behaviours 
taken into consideration by each study included in the systematic review. 
The first general consideration is related to the appropriateness of the demographic 
model used to inform the cost-effectiveness analyses: the prevailing choice is the 
age structured multiple birth cohorts, adopted by six of the eight studies included in 
the review. Only two studies [32,36] used a population-based model. Although 
individual- and cohort-based approaches are generally used in most published 
healthcare decision models, this choice is rarely discussed by the modellers. In a 
cohort-based model, a closed group of individuals who have at least one specific 
dimension in common over a defined period of time (e.g. 12-year-old girls at the time 
of HPV immunisation) is run through a state transition process (e.g. sexual mating, 
infection, clearance or development of HPV-induced malignancies). The cohort is 
generally composed of a pre-defined number of “average” individuals, and the 
resulting population is considered to be a homogeneous group [57]. The risk of 
acquiring a sexually transmitted infection depends on individual-level factors as well 
as the behaviour and infectiousness of others. Consequently, study designs and 
analysis methods developed for studying risk in individuals or cohorts may not apply 
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directly [58]. Structured population models address the heterogeneity of population 
by representing demographic processes in the form of a mathematical function or set 
of functions relating two or more measurable variables. The primary purpose of 
modelling is to make possible an approximate representation of reality in its 
complexity. Contrary to the cohort method, demographic  models allow the social 
and behavioural diversity within the population to be reflected in the outcomes of the 
cost-effectiveness analysis, a crucial aspect that modellers should consider [57]. 
In the case of universal HPV immunisation, most of the characteristics of participants 
and common behaviours representative of their sexual mixing were not included in 
the reviewed publications, regardless of the demographic model chosen. 
Sexual behaviours such as same sex partnership, sex abroad, sex with a partner 
from a different country, and paid sex were almost completely ignored by the eight 
models included in the review. Men having sex with men (MSM) was an input 
included in a single study: a 7% incidence of homosexual males and the relatively 
high risk of disease among MSM vs. heterosexual males would make a two-dose 
universal vaccination more cost-effective that a two-does girls-only immunisation 
[36]. The outcomes of the latest survey of sexual behaviours in the UK show that 8% 
of males have occasional partners of the same sex [29]. 
Taking this argument further, if we compare the most common inputs in models with 
current population characteristics and sexual behaviours within the UK, we see that 
the models within the review do not match the real environment, which leads to a 
lack of ecological validity. Table 3 shows large areas of discord.  
Table 3 should go approximately here. 
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If we reflect on the non-modelled behaviours related to sexual mixing, for example 
with non-UK partners (in the UK or overseas), it is plausible that the models may 
have produced an over-estimation of the impact of herd immunity [35]. If sexual 
partners of unvaccinated males enter the population from countries without a 
vaccination programme, then the vaccination coverage may be significantly lower 
than assumed, altering assumed herd immunity and the subsequent modelled cost-
effectiveness.  
Within the UK, the National Surveys of Sexual Attitudes and Lifestyles (“Natsal”) 
show that, of the cohorts aged 16-24 years old and 25-34 years old, 13.2% (11.5-
15.2%) and 14.5% (12.8-16.5%), respectively, have had at least one new sexual 
partner from outside the UK in the past five years [29,30,59]. It is within these age-
range cohorts that the HPV vaccination programme has been undertaken, and for 
whom herd immunity is now assumed. If unvaccinated partners from overseas are 
entering the modelled population, then the cost-effectiveness outcomes could be 
challenged. 
With this consideration, we re-examined the results of the study closest to ecological 
validity in Figure 2 [36] to appraise possible impact. The study estimates the ICER of 
a 2-dose vaccine protection for 30 years in 14 different scenarios. The 95% 
confidence interval of the mean ICER value was ± 0.21 (i.e. there is 95% certainty 
that the true population mean falls within 21% of the mean value). The impact of 
herd immunity on the percentage reduction in HPV-induced health outcomes 
predicted by cost-effectiveness model can be as large as 50%, as tested in the 
sensitivity analyses of one study included in the review [34]. When we tested a 
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credible hypothesis of 5% to 20% overestimation of QALYs gained in the selective 
immunisation (2-dose girls-only) scenarios, most of the universal ICER values (2-
dose girls + boys) dropped below the acceptability threshold (Table 4). This finding 
was confirmed by another study included in the review [35], where a reduction of 
>15% of the herd immunity benefits lowered the ICER of universal immunisation 
below the $50,000 acceptability threshold. 
Table 4 should go approximately here. 
The results modelled here demonstrate the limitations of the cost-effectiveness 
studies for HPV vaccination, and highlight the concern that public healthcare policy 
might have been built upon incomplete studies. The impact of herd immunity and the 
decision to vaccinate girls and boys, or girls only, must be further defined by 
additional studies that are built upon inputs that are ecologically valid as they are 
truly reflective of the population and its behaviours. The use of a cohort-based 
approach to economic modelling versus a population-based approach (fixed 
population with no further entry, versus one that allows future incident patients to 
enter the population, respectively) has been discussed elsewhere [57], and the 
findings in this systematic review would suggest that the methodological choice of 
individual or cohort-based model is likely to over-estimate the benefits of herd effects 
on the unvaccinated population. A population-based approach to modelling would 
better serve economic decisions attached to HPV vaccination strategies.   
Our findings indicate that the selective immunisation of pre-pubertal girls is likely to 
fail to achieve the expected level of herd immunity at population level. A relatively 
small (15 to 20%) over-estimation of QALY-gained with selective immunisation 
programmes could induce a significant error in the estimate of the cost-effectiveness 
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of universal immunisation, making the option of vaccinating boys cost-ineffective. To 
minimise potential ecological bias, population characteristics and sexual behaviours 
of the modelled population should be aligned more closely to real-life scenarios. This 
would confer ecological validity to the outcomes, it would better inform any resulting 
policy decisions made by public healthcare providers and, ultimately, it would ensure 
the population is best protected against the risk of contracting HPV-induced 
diseases.   
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